Physician profile
Basel Baghal
NPI 1356703409
$1,110.14
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $429 · 2021: $379 · 2022: $226 · 2023: $75.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $75.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $75.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $626.52 | 2020-2023 | Ozempic, Rybelsus |
| Gilead Sciences, INC. | $102.11 | 2020-2021 | |
| Glaxosmithkline, LLC. | $58.60 | 2020-2022 | |
| Lilly USA, LLC | $54.71 | 2020-2021 | |
| Amarin Pharma, INC. | $39.50 | 2020-2021 | |
| Pfizer INC. | $38.49 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $38.41 | 2020-2021 | |
| Endo Pharmaceuticals INC. | $30.00 | 2021 | |
| Arbor Pharmaceuticals, INC. | $27.61 | 2021 | |
| Genentech USA, INC. | $27.15 | 2020 | |
| Redhill Biopharma INC. | $25.67 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $14.66 | 2020 | |
| Janssen Pharmaceuticals, INC | $13.63 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basel Baghal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.